Investment Thesis
Scholar Rock is a pre-revenue biotech company with zero commercial revenue and -$105.5M net losses, burning ~$82M in cash per quarter. While the $430.5M cash position provides ~1.3 years of runway, the fundamental metrics indicate an unsustainable business model dependent entirely on future drug approvals and commercialization success, which remains highly speculative.
Strengths
- Strong cash position of $430.5M relative to $259.2M liabilities provides meaningful runway for development
- Excellent liquidity metrics with 8.64x current ratio indicates ability to meet near-term obligations
- Conservative capital structure with 0.71x Debt/Equity ratio limits financial distress risk
Risks
- Zero revenue with -100% YoY decline reflects complete absence of commercial products or market traction
- Operating losses of -$102M and net losses of -$105.5M demonstrate fundamentally unprofitable operations
- Quarterly cash burn of ~$82M limits runway to approximately 1.3 years at current burn rate without revenue generation or funding
- Negative operating cash flow of -$82.1M and negative ROE (-38.2%) indicate unsustainable economics
- Binary risk profile as pre-revenue biotech dependent on clinical trial success and regulatory approvals
Key Metrics to Watch
- Revenue generation and commercialization milestones for pipeline drugs
- Quarterly cash burn rate and projected runway to profitability or next funding event
- Clinical trial results and regulatory approval progress for development programs
Financial Metrics
Revenue
0.0
Net Income
-105.5M
EPS (Diluted)
$-0.83
Free Cash Flow
-82.2M
Total Assets
535.3M
Cash
430.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-38.2%
ROA
-19.7%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
8.64x
Quick Ratio
8.64x
Debt/Equity
0.71x
Debt/Assets
48.4%
Interest Coverage
-16.19x
Long-term Debt
196.6M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-09T13:13:27.661522 |
Data as of: 2026-03-31 |
Powered by Claude AI